TipRanks
Go Ultimate55% OFF

Pa Shun International Holdings Limited (0574) AI Stock Analysis

Top Page

HK:0574

Pa Shun International Holdings Limited

(HKEX:0574)

Select Model
Rating:40Underperform
Price Target:HKD 0.02â–¼(-5.56% Downside)
Action:reiterated
Date:09/26/26

The score is primarily weighed down by weak financial performance—persistent negative equity, recurring losses, and consistently negative operating/free cash flow. Technicals also remain soft with the price below key long-term moving averages and a negative MACD, with only a modest offset from a near-oversold RSI reading. Valuation is difficult to assess due to the negative P/E driven by losses and no dividend yield data.

Positive Factors
Improved operating profitabilityPositive operating profit and EBITDA in 2025 indicate that the core business can generate operating earnings under improved conditions. Although profitability remains thin and has not reached the bottom line, this provides a foundation for potential earnings repair if operating performance is sustained.
Negative Factors
Persistent negative equityPersistently negative shareholders’ equity is a major solvency weakness and leaves the company with limited financial flexibility. It can restrict access to funding, increase dependence on creditors or asset disposals, and make the business more vulnerable if losses or cash needs continue.

Pa Shun International Holdings Limited (0574) vs. iShares MSCI Hong Kong ETF (EWH)

-60%-40%-20%0%20%40%60%HK:0574-48.57%EWH+7.37%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Market Cap
HKD 35.83M
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-1.4
Beta (1Y)
-0.14
Revenue Growth
0.21%
EPS Growth
-2.33%
Country
Hong Kong
Employees
108
Sector
Healthcare
Sector Strength
51
Industry
Medical - Pharmaceuticals

Pa Shun International Holdings Limited Business Overview & Revenue Model

Company Description

Pa Shun International Holdings Limited, an investment holding company, engages in the pharmaceutical distribution and manufacturing businesses in the People's Republic of China. The company sells pharmaceutical products to wholesalers, hospitals, and...

Pa Shun International Holdings Limited Financial Statement Overview

Summary

Overall financial quality is weak: recurring net losses (including 2024–2025), persistently negative shareholders’ equity (2021–2025) indicating elevated solvency risk, and consistently negative operating/free cash flow across all years shown. While there were pockets of improvement (a 2023 rebound and positive operating profit/EBITDA in 2025), they have not translated into sustained profitability or cash generation.

Income Statement

28Negative

Balance Sheet

18Very Negative

Cash Flow

12Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue86.81M86.81M86.55M129.43M71.78M85.91M
Gross Profit12.01M12.01M17.06M29.43M13.30M11.06M
EBITDA7.54M7.53M2.89M19.65M-2.30M-10.70M
Net Income-15.86M-15.86M-15.31M2.35M-43.38M-330.40M
Balance Sheet
Total Assets169.78M169.78M179.65M206.57M136.09M468.59M
Cash, Cash Equivalents and Short-Term Investments5.53M5.53M15.97M16.51M1.90M2.27M
Total Debt205.79M45.48M44.03M165.97M108.71M99.01M
Total Liabilities297.34M297.34M315.68M322.67M251.60M251.59M
Stockholders Equity-148.04M-148.04M-136.04M-116.10M-115.52M-58.50M
Cash Flow
Free Cash Flow-12.08M-11.71M-1.77M-35.00M-2.35M-22.12M
Operating Cash Flow-10.93M-10.57M-1.68M-34.93M-2.32M-21.89M
Investing Cash Flow-1.17M-1.15M-88.00K-65.00K2.98M24.97M
Financing Cash Flow1.39M1.54M1.23M49.61M-1.02M-6.07M

Pa Shun International Holdings Limited Technical Analysis

Technical Analysis SentimentNegative
Last Price0.02

Price Trends

50DMA0.02Positive
100DMA0.02Negative
200DMA0.03Negative

Market Momentum

MACD-0.00Negative
RSI35.65Neutral
STOCH100.00Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0574, the sentiment is Negative. The current price of 0.02 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.03, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 35.65 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0574.

Pa Shun International Holdings Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

HK:0574 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
HK:0239HK:023977OutperformHKD 774.43M7.7613.59%7.44%10.63%39.44%
HK:3613HK:361372OutperformHKD 4.73B10.2311.15%6.55%-20.79%-30.04%
HK:0950HK:095068NeutralHKD 606.50M3.648.02%5.61%7.05%22.46%
HK:0897HK:089759NeutralHKD 401.18M100.000.34%―-8.30%-44.44%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
HK:0455HK:045544NeutralHKD 191.35M-2.73-14.55%―12.89%-2.56%
HK:0574HK:057440UnderperformHKD 35.83M-1.4210.70%―0.21%-2.33%

* Healthcare Sector Average

Performance Comparison

-40%-20%0%20%HK:0574HK:3613HK:0455HK:0897HK:0950HK:0239Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
HK:0574 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
HK:0574Pa Shun International Holdings Limited0.02-0.02-55.00%
HK:3613Beijing Tong Ren Tang Chinese Medicine Co 5.65-2.58-31.38%
HK:0455Tianda Pharmaceuticals Ltd.0.09-0.05-34.07%
HK:0897Wai Yuen Tong Medicine Holdings Limited0.36-0.10-21.74%
HK:0950Lee's Pharmaceutical Holdings Limited1.03-0.77-42.94%
HK:0239Pak Fah Yeow International Limited2.480.2511.09%

Pa Shun International Holdings Limited Corporate Events

Pa Shun International Winding-Up Petition Hearing Adjourned as Share Suspension Continues

Sep 16, 2026

Pa Shun International Holdings Limited has announced that the court hearing of a winding-up petition against the company, originally referenced in earlier announcements, was held on 16 September 2026 and has been adjourned to 21 October 2026. The com...

Pa Shun Faces Winding-Up Petition Over Unpaid HK$8 Million Loan

Sep 1, 2026

Pa Shun International Holdings Limited has disclosed that a creditor has filed a winding-up petition in the Hong Kong High Court over the company’s failure to repay a HK$8 million loan, plus accrued interest, that was taken for general working...

Pa Shun Flags Delay in 2026 Interim Results as Receivers Control PRC Units

Aug 24, 2026

Pa Shun International Holdings Limited has warned that it will miss the statutory deadlines for publishing its interim results and sending its interim report for the six months to 30 June 2026, after receivers took control of its PRC subsidiaries and...

Pa Shun International’s Requisitioned EGM Dissolved as Share Trading Remains Suspended

Jul 21, 2026

Pa Shun International Holdings Limited, a Cayman Islands-incorporated investment holding company listed in Hong Kong under stock code 574, is overseen by a board led by Chairman and executive director Yuan Hongbing alongside two independent non-execu...

Pa Shun International warned on trading resumption and potential delisting risk

Jul 16, 2026

Pa Shun International Holdings has disclosed that the Stock Exchange of Hong Kong has issued formal resumption guidance setting out conditions that must be met before trading in the company’s shares can restart. The exchange is requiring the co...

Pa Shun International Shareholders Approve All AGM Resolutions Amid Director Vote Imbalance

Jul 7, 2026

Pa Shun International Holdings Limited reported that all resolutions put to shareholders at its adjourned annual general meeting on 7 July 2026 were approved by poll. Shareholders representing about 59% of the company’s issued share capital wer...

Pa Shun International Clarifies Board and Committee Structure

Jul 7, 2026

Pa Shun International Holdings Limited has disclosed an updated list of its directors and clarified their respective roles and functions on the board. The company confirms that its board comprises one executive director, chairman Yuan Hongbing, and t...

Pa Shun Faces Receivership Over Key Pharma Assets After Scheme Default

Jul 2, 2026

Pa Shun International Holdings has defaulted on a HK$10 million yearly payment due under its court-sanctioned scheme of arrangement, triggering enforcement of a debenture secured over assets of its key pharmaceutical subsidiary. The scheme, which had...

Pa Shun International Halts Trading Pending Inside Information Announcement

Jul 2, 2026

Pa Shun International Holdings Limited, a Cayman Islands-incorporated company listed on the Hong Kong Stock Exchange under stock code 574, has a board composed of executive, non-executive and independent non-executive directors in line with typical H...

Pa Shun International Adjourns AGM After Lack of Quorum, Resets for July 7

Jun 30, 2026

Pa Shun International Holdings Limited has adjourned its annual general meeting originally scheduled for June 30, 2026, after failing to reach a quorum within the first 30 minutes as required under its articles of association. The meeting has been re...

Pa Shun International’s Shareholder-Requisitioned EGM Dissolved for Lack of Quorum

Jun 26, 2026

Pa Shun International Holdings Limited, a Cayman Islands-incorporated company listed in Hong Kong, maintains a board composed of executive, non-executive and independent non-executive directors, consistent with governance norms for listed entities. T...

Pa Shun International Faces Winding-Up Petition Over HK$8 Million Loan Default

Jun 26, 2026

Pa Shun International Holdings Limited has disclosed that a creditor, Underdog Consulting Limited, has filed a winding-up petition in the Hong Kong High Court, alleging the company failed to repay a HK$8 million loan principal that fell due in Novemb...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 26, 2026